Overview
Founded in 2017, InxMed is a late clinical-stage biotechnology company dedicated to tackling a central challenge in cancer therapy—drug resistance caused by tumor defense mechanisms. Our strategy focuses on critical signaling hubs shared across multiple tumor types, most notably the focal adhesion kinase (FAK) and integrin pathways, which play pivotal roles in tumor cell survival and contribute to treatment failure across various therapeutic modalities. In parallel, we target cancer-associated fibroblasts (CAFs) to dismantle the protective barrier around tumor cells. Through these integrated efforts, we aim to redefine cancer treatment and pioneer new frontiers in therapeutic innovation.
InxMed has established a highly differentiated pipeline focused on overcoming tumor defense mechanisms. Our lead program, ifebemtinib, is currently in the registrational stage and has been granted Breakthrough Therapy Designation by the China National Medical Products Administration (NMPA) as well as Fast Track Designation by the U.S. FDA. Additionally, several highly innovative preclinical candidates, which demonstrate synergy with our clinical-stage assets, are advancing toward clinical studies.
Members of InxMed’s management team have held senior R&D and commercial roles in top-tier multinational pharmaceutical companies. They possess extensive experience in advancing more than 100 clinical assets into clinical development and have led over 20 clinical programs resulting in New Drug Application (NDA) approvals in both China and the United States.
InxMed operates in both the United States and China. We are a passionate, energetic, and creative team united by a strong belief in doing "extraordinary things" to transform cancer treatment.
History
Aug，2025
Received the third Breakthrough Therapy Designation by China NMPA for 2L+ CRC with KRAS G12C Mutation
Aug，2025
Closed US $33.72M Series C Financing
Apr，2025
Opening of InxMed Shenzhen office
Nov，2024
Received Breakthrough Therapy Designation by China NMPA for 1L NSCLC with KRAS G12C Mutation
Oct，2024
Released data Ifebemtinib improving therapeutic window of ADC at 15th Annual World ADC
Jun，2024
Released Positive Phase Ib/II Results for Ifebemtinib in Combination with Garsorasib in 1L NSCLC with KRAS G12C Mutation
Vision
With a deep-rooted understanding of disease biology driving our innovation, InxMed is dedicated to becoming a global pioneer in transformative cancer therapies.
Mission
Our mission is to address a core challenge in oncology — the emerging treatment resistance that attributes to tumor defense system.
Leadership Team
Zaiqi Wang M.D.,Ph.D.
Dr. Zaiqi Wang,is a founder of our Group. He was appointed as a Director and our chief executive officer on November 29, 2018. He is primarily responsible for the overall strategic planning and making key business and operational decisions of the Group. Dr. Zaiqi has extensive experience in pharmaceutical research and development, clinical development, and corporate management within the global biopharmaceutical industry. Dr.Wang served as a resident in internal medicine at Union Memorial Hospital in the United States from June 1995 to June 1998. Subsequently, Dr. Zaiqi held the position of director of clinical research and experimental medicine at Schering-Plough Corporation (currently known as Merck & Co., Inc.), a pharmaceutical company formerly listed on the New York Stock Exchange (stock code: SGP), in the United States from January 2001 to March 2009. From April 2009 to June 2011, he was the director of clinical research in the Translational Medicine Center (Singapore) of Merck & Co., Inc., a New York Stock Exchange-listed company (stock code: MRK), and he subsequently served in Merck & Co., Inc. (China) with his last position as head of clinical research from June 2011 to November 2017. Prior to co-founding our Group,Dr. Zaiqi served as the head of the R&D innovation center at the Shanghai Innovation Center of Roche China from December 2017 to December 2018.Dr. Zaiqi served as the vice chair of the DIA Drug Discovery Innovation (DDI)Conference in 2018 and as chair in 2019. He is an editorial board member of Clinical and Translational Research. Dr. Zaiqi obtained the medical license for clinical pharmacology in 2001 and the medical license for internal medicine in 2008. In August 2020, Dr. Zaiqi was recognized as a “Jiangbei New Area High-level Entrepreneurial Talent” . Dr. Zaiqi received his bachelor’s degree in medicine from Henan Medical College of Zhengzhou University in the PRC in August 1983. He obtained his doctor’s degree from Virginia Polytechnic Institute and State University in the United States in August 1992. He also finished his post-doctoral research in Johns Hopkins School of Medicine in the United States in June 1995.
Read More >>
Fei Cao
Mr. Fei Cao ,is a co-founder of our Group. He was appointed as a Director, our chief operating officer and acting chief financial officer on November 29, 2018.He is primarily responsible for the overall strategic planning and making key business and operational decisions of the Group. Mr. Fei Cao has over 15 years of experience in management, operations and business development in the biotechnology and pharmaceutical industry. From May 2004 to August 2007, Mr. Fei Cao served as an assistant director of the investment and financing department at CapitalBio Corporation, during which he also served as a business development manager from May 2004 to October 2006. From August 2007 to June 2009, he was a business development manager for Greater China at GlaxoSmithKline (China) Investment Co., Ltd , a subsidiary of GlaxoSmithKline PLC, which is a company listed on the NewYork Stock Exchange (stock code: GSK) and the London Stock Exchange (stock code: GSK). From June 2009 to September 2011,Mr. Fei Cao served as a senior manager of business development at Xi’an Janssen Pharmaceutical Ltd., a subsidiary of Johnson & Johnson, a company listed on the New York Stock Exchange (stock code: JNJ), during which he also served as manager of external affairs and business development at Janssen Asia Pacific R&D Center from June 2009 to March 2011. From September 2011 to November 2012, he was a senior director of government affairs and a member of the senior management committee at BeiGene (Beijing) Biotech Co., Ltd. , a subsidiary of BeOne Medicines Ltd (formerly known as BeiGene, Ltd.) , which is a company listed on the Stock Exchange (stock code: 6160), the Shanghai Stock Exchange (stock code: 688235) and the NASDAQ Stock Exchange (stock code: ONC). Prior to co-founding our Group, Mr. Fei Cao served as the co-founder and chief executive officer of Corestone Biosciences (Beijing) Co., Ltd. from December 2015 to October 2018. Mr. Fei Cao received his bachelor of science degree and his bachelor of economics degree (double degree) from Peking University in the PRC in July 2001. He enrolled in the PhD program and conducted study and research at the Hong Kong University of Science and Technology from August 2001 to March 2003.Mr. Fei Cao was a research assistant at Thomas Jefferson University and the University of Pennsylvania in the United States from March 2003 to March 2004.
Read More >>
Anfeng Guo
Mr. Anfeng Guo, was appointed as our chief commercial officer in September 1, 2022. He is primarily responsible for the overall strategic planning of the Group’s commercial markets. Mr. Anfeng Guo has over 20 years of experience in the pharmaceutical industry. From October 2017 to April 2000, Mr. Anfeng Guo was the head of sales of the Immuno-Oncology Lung Cancer Indications Business Unit at Bristol Myers Squibb, a company listed on the New York Stock Exchange (stock code: BMY). He served as the chief commercial officer at LinkDoc Technology (Beijing) Co., Ltd. from February 2021 to September 2022. Mr. Anfeng Guo received his bachelor’s degree in biological pharmacy from Nanjing University of Technologyin the PRC in June 2000. He obtained his Master of Business Administration degree from Nanjing Universityin the PRC in November 2018.
Read More >>
Jie Ding Ph.D.
Dr. Jie Ding joined InxMed in January 2023. He spent more than twenty years in the pharmaceutical industry with experiences across the entire new medicine development spectrum from preclinical discovery research to late phase clinical development with multiple successful global NDA and sNDA registrations mainly in the oncology area. Dr. Ding started his career at GlaxoSmithKline (2002~2016). During 2007~2011, Dr. Ding was the lead Principle Statistician for the VEGF inhibitor Pazopanib in the Advanced RCC indication (approved by FDA in 2009) and several other indications including HCC, Thyroid, Sarcoma, etc. In 2016, Dr. Ding joined Merck & Co. (MSD), and his work directly led to FDA accelerated approval of Keytruda in the MSI-High Pan tumor indication (2017), the first ever pan tumor agnostic indication in history. From 2017 to 2021, Dr. Ding returned to Beijing and was Sr. Director and head of Biostatistics & Research Decision Science – Asia Pacific (BARDS-AP) at Merck (MSD). He and his team of 50+ statisticians and programmers in BARDS-AP successfully supported multiple NDA and sNDA including Keytruda and other medicines in the US, EU and Asia Pacific regions (China and Japan) in a little over three years. From 2021 to 2022, Dr. Ding was the Executive Director and head of Biostatistics at the Sumitomo Pharma Oncology in Cambridge, Massachusetts. Dr. Ding holds a Bachelor’s degree in Mathematics from Nankai University and a Ph.D. degree in Statistics from Temple University.
Read More >>
Management Team
Shuang Xie M.D.,Ph.D.
Vice President，Clinical Development
Ms. Shuang Xie joined InxMed in February 2019 and currently serves as Vice President, Clinical Development. From 2013 to 2018, she worked in MSD China Development Center as Early development head of Clinical research department. From 2009 to 2013, Shuang served in Fuwai Hospital as the Phase I Clinical Head and completed up to 10 Phase I clinical studies. Prior to this, Shuang worked in Beijing Chaoyang Hospital as an oncologist for about 10 years. Shuang received her Bachelor degree from Capital Medical University. She holds Master's degree and Ph.D. from Medical Science Center of Peking University and Union Medical College respectively.
Read More >>
Rangrong Li
Vice President，Clinical Operation
Ms. Rangrong Li joined InxMed in April 2019 and currently serves as Vice President, Clinical Operation. Rangrong has more than 14 years work experience on clinical operation of pharmaceutical industry. She was involved in 7 products successfully launched in market working in different roles. Prior to joining InxMed, Rangrong served as Director, Clinical Operation at Medpace Inc from 2018 to 2019. From 2005 to 2018, Rangrong had been working in the Global Clinical Trial Operation team at MSD China R&D taking increasing responsibilities from Clinical Research Manager to Associate Director. Before joining the pharmaceutical industry, she had 17 years of work experience in public hospitals. She holds Bachelor's degree of Medical Science from Capital Medical University.
Read More >>
Baoyuan Zhang Ph.D.
Vice President，Translational Medicine
Mr. Baoyuan Zhang joined InxMed in Sept 2019 and currently serves as Vice President, Translational Medicine. He has rich work experience in innovative drug research and translational medicine. He previously worked in Chempartner and WuXi AppTec, and acted as senior scientist for translational research and bioinformatics in the oncology department. Dr. Baoyuan Zhang graduated from the University of Macau to lead the project entitled “Synthetic lethality discovery for BRCA1 deficient breast cancer”. The project won the best research award at the Korean Biomedical Conference, in 2017. He has already published 15 scientific research articles as first author or corresponding author in top-tier journals including Advanced Science, Nature Communications, Cancer Research, and Oncogene. Dr. Baoyuan Zhang holds a bachelor's degree in biochemistry, a master's degree in pharmacology, and a Ph. D. in biomedical science.
Read More >>
Yi Huang Ph.D.
Vice President，External Affairs and Investor Relations
Dr. Yi Huang, joined the Company in January 2022 and currently serves as Vice President，External Affairs and Investor Relations. From July 2015 to May 2017, he served in the research department of Zhong De Securities Company Limited , where he was responsible for industry research and providing support for investment banking business. He worked at Morningside Venture Limited from July 2017 to December 2021, where he was responsible for investments in innovative drugs. Dr. Yi Huang received his bachelor’s degree in life science and technology from Wuhan University in the PRC in June 2008. He obtained his doctor’s degree in biochemistry and molecular biology from Peking Union Medical College/Tsinghua University School of Medicine(National Institute of Biological Sciences,Beijing) in the PRC in July 2013.
Read More >>
Yi Ren
Vice President，Human Resources
Ms. Yi Ren joined InxMed in November 2019 and currently serves as Vice President， Human Resources. With nearly 20 years of HR experience spanning multiple industries, she possesses extensive expertise in the systematic management of multinational corporations in China, organizational transformation of local enterprises, and building HR frameworks from scratch in startups. She has particularly deep insight and understanding of the healthcare and wellness sector. Prior to joining InxMed, she served as Human Resources Director at the local enterprise Care Doppler Medical Group. Before that, she held HR roles at NIO, B. Braun Medical, Bertelsmann, Danfoss, and Alcatel-Lucent Shanghai Bell, contributing significantly to HR system development, corporate governance transformation, corporate culture shaping, and talent system construction across companies at various growth stages. Ms. Yi Ren earned her Bachelor’s degree in Electrical Engineering from Tongji University and later obtained a Master’s degree in Psychology from UCAM University.
Read More >>
Yanan Liu,Ph.D.
Vice President，Portfolio Management
Ms. Yanan Liu joined InxMed in November 2018 and currently serves as Vice President, Portfolio Management. Yanan Liu has more than ten years work experience in the world’s leading multinational companies in the pharmaceutical industry. Her roles span from medical, and regulatory to project/pipeline management. She has been leading and coordinating chemical and biological product development and registration projects in China as well as global markets. Her recent responsibilities include MSD/Merck Co (NYSE: MRK) Project Management Associate Director since October 2013, previously she had also been working in GlaxoSmithKline (LSE: GSK, NYSE: GSK) and PAREXEL International. Yanan got her Bachelor's degree and Ph.D. from the Medical Science Center of Peking University. She also holds an MBA from Peking University. Yanan is a Certified Project Manager (CPM). Yanan now lives with her two lovely children and husband in New Zealand.
Read More >>
Liyuan Liu
Executive Director，CMC
Ms. Liyuan Liu joined InxMed in March 2023 and currently serves as Executive Director, CMC (Chemical, Manufacture and Control). She has more than 10 years of work experience in the field of CMC. She had involved multiple projects and 9 products were successfully launched in the market, and 11 patents were granted. Prior to joining Inxmed, she was Vice President of Noventi, responsible for innovative drug development from 2020 to 2023. Prior to that she worked as PM and director in Cinkate Corporation and Jingfeng Pharmaceutical from 2010 to 2020 respectively. Liyuan Liu holds Master degree in Pharmaceutics of the Shanghai Institute of Pharmaceutical Industry.
Read More >>
Libo Gao
Senior Director，Drug Safety
Ms. Libo Gao joined InxMed in Sep 2019 and currently serves as Senior Director, Drug Safety. Libo Gao has the background in Clinical Medicine Biochemistry & Molecular Biology. Since Apr. of 2008, Libo Gao has been working in the Drug Safety & Pharmacovigilance field in Pharmaceutical Companies including MSD, Novartis, Takeda and Mundipharma involving in clinical development and post-marketing activities in therapeutic areas of Pain, Ophthalmology, Transplantation, Endocrinology, Digestion and oncology etc. Libo Gao held a Master's degree of Biochemistry from Peking University Health Science Center.
Read More >>
Juan Wang
Senior Director，Medical Liaison Sales
Ms. Juan Wang joined InxMed in 2023 and currently serves as Senior Director, Medical Liaison Sales.With over 20 years of experience in the pharmaceutical industry, Ms. Juan Wang has previously held positions at several Fortune 500 pharmaceutical companies, including Merck & Co., Inc., Pfizer Inc., and Novartis. She has accumulated extensive management expertise in commercial operations, market access, and clinical recruitment/patient enrollment. Throughout her career, she has contributed to the team formation and market-clinical promotion for the launch of multiple innovative products in China. Ms. Juan Wang graduated from the Department of Economics, Nankai University (Tianjin).
Read More >>
Li Yang
Senior Director，Quality
Mr. Li Yang currently serves as Senior Director,Quality. Mr. Li Yang has over ten years of experience in the pharmaceutical industry. He has held positions at companies including NHU Group, Hanmi Pharmaceutical, Sihuan Pharmaceutical Group, and Pharmaron, where he accumulated extensive expertise in drug R&D, clinical auditing, quality system development, and quality management across small-molecule drugs, multi-component biochemical drugs, biologics, and cell and gene therapies (CGT). He has led or contributed to the Investigational New Drug (IND) applications of more than 20 products and the successful market launch of 7 products (including both generics and innovative drugs). Mr. Li Yang has overseen the construction of 6 manufacturing facilities, all of which successfully obtained Drug Manufacturing Licenses (including Type A, B, C, and D certifications in China). He has also led multiple company preparations and passed on-site inspections for research and manufacturing conducted by regulatory authorities such as the NMPA, EMA, and WHO. Mr. Li Yang holds a Bachelor of Pharmacy degree from Jilin Medical University (formerly the Jilin Military Medical College of the Fourth Military Medical University).
Read More >>
Fengmin Xi
Senior Director，DMPK
Mr. Fengmin Xi joined InxMed in March 2023 and currently serves as DMPK Senior Director. Fengmin has more than 10 years of R&D experience in DMPK, toxicology, and medicinal chemistry, additionally, along with rich investment and financing skills in biotechnology. He was previously employed in a biotech boutique investment bank, HollyHigh, and engaged in investment and financing for biotech and CXO companies. Prior to that, he worked for WuXi AppTec (603259. SH/2359.HK) and Medicilon (688202. SH) in clinical bioanalysis, preclinical DMPK, and toxicology. He held a Ph.D. in medicinal chemistry at Peking Union Medical College and Tsinghua University.
Read More >>
Zhaobin Zeng
Senior Director，Regulatory Affairs
Mr. Zhaobin Zeng joined InxMed in July 2023 and currently serves as Senior Director, Regulatory Affairs. Zhaobin has more than 20 years experience in drug product registrations working at a high level of competency. Served in a variety of RA positions of increasing responsibility with Abogenbio, Junshi Pharma, and Hengrui Pharma， successfully applied for several NDA and IND applications for Innovation Drugs. Essential knowledge of international and Chinese regulations as well as technical guidance with strong communication and team leadership skills. He held Bachelor's degree in Pharmacy from the Medical Science Center of Peking University.
Read More >>
Xiong Mao
Director，Statistical Programming
Mr. Xiong Mao joined InxMed in January 2024 and currently serves as Director, Statistical Programming.With over twelve years of extensive experience in statistical programming for pharmaceutical clinical development since 2013, Mr. Xiong Mao has held clinical statistical programming roles at leading domestic and international organizations, including Parexel, Tigermed, and AstraZeneca. He is proficient in CDISC standards and skilled in core tools such as SAS and Python. Mr. Xiong Mao possesses deep technical expertise and substantial hands-on project experience in clinical data management, statistical analysis, reporting, regulatory submission, and vendor management. He earned his master’s degree from Jiangnan University in 2013.
Read More >>
Changlan Zhu
Director，BD
Ms.Changlan Zhu joined InxMed in August 2025 as Director of Business Development (BD). With over a decade of experience in the pharmaceutical industry, Ms.Changlan Zhu specializes in corporate strategy planning and pharmaceutical business development. She has previously held positions at multinational pharmaceutical companies including GlaxoSmithKline and Sumitomo Pharma, and possesses a global perspective, successful entrepreneurial experience, and a cross-disciplinary background in AI-driven drug discovery. Throughout her career, she has successfully incubated and executed five overseas collaboration projects, which subsequently secured investment from renowned investment institutions, and has led one cross-border M&A transaction. Ms.Changlan Zhu has extensive experience in pharmaceutical deal-making, resource integration, and commercial negotiations. Ms.Changlan Zhu holds a Bachelor of Science degree from the Enhanced Program in Biochemical Pharmacy at Nanjing University and a graduate degree from the Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences.
Read More >>
Shuoyun Zhou
Director，Finance
Ms. Shuoyun Zhou currently serves as Director,Finance.Since joining InxMed in 2018, as a founding member and core leader of the company's financial system, she has been fully involved in and driven the leapfrog development of the finance function from a startup setup to a systematic and professional structure. She led the establishment of the financial framework from the ground up, creating a financial accounting and budgeting management system that supports business growth. Across multiple rounds of financing and M&A projects, she has been deeply engaged in preliminary due diligence as well as post-transaction fund deployment and integration support. She has also facilitated banking partnerships, including securing credit facilities, laying a solid financial foundation for the company’s business expansion and sustainable operations.
Read More >>
Key Contacts
Corporate Communications
Business Development
InxMed Nanjing Head Office
ADD: 73 Tanmi Road Block D-2, Jiangbei New District, Nanjing
Tel: +86 25-58251030
InxMed Shanghai Office
ADD: 515 Huanke Road, Greenland M-Town Tower 1, Room 602-603 Pudong
Tel: +86 21-50630108
InxMed Beijing Office
ADD: Room 2308-2310，Tower 8，No.91 Jianguo Rd.,Chaoyang District,Beijing
Tel: +86 10-85887500
InxMed Shenzhen Office
ADD: A1703 Innovation Plaza, No. 2007 Pingshan Avenue,
Liulian Community, Pingshan Street, Shenzhen
Tel: +86 755-28824008
Online Message
QUICK LINKS
CONTACT US
Tel: +86 25-58251030
Email: office@inxmed.com
Office address: 73 Tanmi Road Block D-2, 3rd Floor Jiangbei New District, Nanjing
MESSAGE